Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Oct 31 - Nov 5
Preliminary human research suggests that tirzepatide may enhance insulin sensitivity more efficiently than selective GLP-1 receptor agonists, challenging the notion that weight loss is the sole contributor to improved insulin sensitivity
Currently, Wegovy targets one hormone (GLP-1), and Zepbound targets two (GLP-1 and GIP)
PlexusDx GLP-1 medications are HSA and FSA eligible, allowing uninsured patients to redirect tax-advantaged savings toward treatment
Primary buyer fit: academic and contract research laboratories
The points to watch are your weight crossing the 60 kg threshold for apixaban dosing, and taking rivaroxaban with a proper meal, even when your appetite is lower
Clinician review occurs after intake submission, and prescriptions are issued only if a clinician authorizes them, with fulfillment handled downstream by pharmacies
